When the protection runs out...a new submission....time released medication to keep the medication in the forefront and battle with generic equivalents that enter the market...BD
AstraZeneca announced that the company has submitted two separate supplemental New Drug Applications (sNDAs) to the U.S. Food and Drug Administration (FDA) for once-daily SEROQUEL XR™ (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of manic episodes associated with bipolar disorder and the treatment of depressive episodes associated with bipolar disorder.
SEROQUEL XR is currently approved in 8 countries including US, Canada and The Netherlands, for the acute and maintenance treatment of schizophrenia in adults.
0 comments :
Post a Comment